Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Med Sci Monit ; 25: 5306-5311, 2019 Jul 17.
Article in English | MEDLINE | ID: mdl-31313754

ABSTRACT

BACKGROUND The relationships between culprit coronary plaque characteristics and hyperhomocysteinemia (HHcy) are not fully understood in young patients. In this study we investigated the relationship between culprit atherosclerotic plaque phenotype assessed by optical coherence tomography (OCT) and hyperhomocysteinemia (HHcy) in young patients. MATERIAL AND METHODS We investigated the OCT imaging and HHcy of 123 lesions in 123 young patients (≤45 years of age). According to OCT images, culprit lesions were classified as thin-cap fiber atheroma (TCFA), thrombus, and other. The 123 patients were grouped as: HHcy group (53 cases, HHcy ≥15.5 µmol/l) and control group (70 cases, HHcy <15.5 µmol/l). RESULTS Compared with the control group, the HHcy group had a higher proportion of OCT-TCFA (p=0.03), OCT-vasa vasorum (p=0.013), and OCT-thrombus (p=0.012), and a larger lipid arc (p=0.002). HHcy (P=0.037) and metabolic syndrome (MetS) (P=0.016) remained independent predictors of TCFAs. HHcy (P=0.026) and smoking (P=0.005) remained independent determinants of thrombus. CONCLUSIONS HHcy and MetS are associated with TCFAs, and HHcy and smoking are associated with thrombus in young patients with coronary artery disease.


Subject(s)
Coronary Artery Disease/complications , Hyperhomocysteinemia/physiopathology , Plaque, Atherosclerotic/pathology , Acute Coronary Syndrome/complications , Adult , China , Coronary Angiography/methods , Coronary Artery Disease/etiology , Coronary Vessels/pathology , Female , Humans , Hyperhomocysteinemia/complications , Male , Overweight , Plaque, Atherosclerotic/metabolism , Predictive Value of Tests , Retrospective Studies , Smoking , Tomography, Optical Coherence/methods
2.
Cancer Chemother Pharmacol ; 79(5): 1003-1011, 2017 May.
Article in English | MEDLINE | ID: mdl-28391353

ABSTRACT

PURPOSE: The mechanisms underlying the oncogenic properties of WW domain binding protein 2 (WBP2) in breast cancer have not been fully understood. In this study, we explored the role of WBP2 in cell cycle regulation in ER+ breast cancer cells and how it is regulated in the cancer cells. METHODS: The association between WBP2 expression and prognosis in ER+ breast cancer was assessed by data mining in Breast Cancer Gene-Expression Miner v4.0. Cell cycle was assessed by PI staining and flow cytometry. EdU staining was applied to visualize cells in S phase. The binding between miR-206 and WBP2 were verified by dual luciferase assay. CCK-8 assay and flow cytometric analysis were applied to assess the functional role of WBP2 and miR-206 in the cancer cells. RESULTS: High WBP2 expression correlates with higher risk of any events (AE) and metastatic relapse (MR) and also indicates shorter AE-free survival and MR-free survival in ER+ breast cancer patients. In both MCF-7 and BT474 cells, WBP can influence the expression of G1/S-related cell cycle proteins, including p21, CDK4, and cyclin D1. In addition, WBP2 overexpression resulted in facilitated G1/S transition, while WBP2 knockdown impaired the transition. The 3'UTR of WBP2 has a conserved miR-206 binding site. Functionally, miR-206 knockdown decreased tamoxifen sensitivity in tamoxifen-sensitive (TamS) MCF-7 cells, while miR-206 overexpression and WBP2 knockdown enhanced the sensitivity in tamoxifen-resistant (TamR) MCF-7 cells. CONCLUSION: Based on these findings, we infer that the miR-206/WBP2 axis can modulate tamoxifen sensitivity via regulating G1/S progression in ER+ breast cancer.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Breast Neoplasms/genetics , Breast Neoplasms/pathology , G1 Phase/genetics , MicroRNAs/genetics , Receptors, Estrogen/genetics , S Phase/genetics , 3' Untranslated Regions/genetics , Antineoplastic Agents, Hormonal/pharmacology , Binding Sites , Cell Cycle Proteins/genetics , Cell Line, Tumor , Cell Survival/drug effects , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , Female , Gene Knockdown Techniques , Humans , MCF-7 Cells , Prognosis , Tamoxifen/pharmacology , Trans-Activators
3.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 23(5): 1292-5, 2015 Oct.
Article in Chinese | MEDLINE | ID: mdl-26524025

ABSTRACT

OBJECTIVE: To investigate the efficacy of arsenic trioxide combined with all trans retinoic acid (ATRA) for patients with acute promyelocytic leukemia (APL). METHODS: A total of 159 cases of APL were selected from January 2011 to December 2014 in our hospital, among them 75 cases were treated by As2O3combined with ATRA, 43 cases were treated with As2O3alone, 41 cases were treated with ATRA alone. The cardiac enzymes level, lever function index change, death rate, complate remission (CR) rate, time of reaching CR and complicatiens were compared in 3 groups. RESULTS: After treatment of 8 courses, ALT and AST levels in As2O3+ ATRA group were significantly higher than those in As2O3and ATRA alone groups; the CK-MB and TnI-UI index increased in As2O3group (P < 0.05); as compared with As2O3group, the mortality and CR rate in As2O3+ ATRA group were no significant different, but the time of reaching CR was significantly shortened. For relapsed patients, the CR rate in As2O3+ ATRA group was no significantly different from that in As2O3group, while was significantly higher than that in ATRA group. The ratio of liver function damage in As2O3+ ATRA group was increased, moreover the incidence of leukocytosis and headache in ATRA group was significantly higher than that in As2O3+ ATRA and As2O3group (P < 0.05). CONCLUSIONS: The efficacy of As2O3conbined with ATRA for inducing remission is better than that of single drug treatment, moreover the adverse reactions occur less.


Subject(s)
Arsenicals/therapeutic use , Leukemia, Promyelocytic, Acute/drug therapy , Oxides/therapeutic use , Tretinoin/therapeutic use , Arsenic Trioxide , Drug Therapy, Combination , Humans , Remission Induction
4.
Med Sci Monit ; 21: 1297-303, 2015 May 06.
Article in English | MEDLINE | ID: mdl-25943633

ABSTRACT

BACKGROUND: MiR-27a is significantly overexpressed in triple-negative breast cancer (TNBC). However, the exact biological function of MiR-27a in TNBC is not fully understood. In this study, we verified miR-27a expression in TNBC cells and explored how its overexpression modulates radiosensitivity of the cells. MATERIAL/METHODS: qRT-PCR analysis was performed to study miR-27a expression in TNBC lines MDA-MB-435 and MDA-MB-231 and in normal human breast epithelial cell line MCF10A. Dual luciferase assay was performed to verify a putative downstream target of miR-27a, CDC27. CCK-8 assay was used to assess the influence of miR-27a-CDC27 axis on cell proliferation under irradiation (IR) treatment. RESULTS: We confirmed significantly higher miR-27a expression in 2 TNBC cell lines--MDA-MB-435 and MDA-MB-231--than in human breast epithelial cell line MCF10A. miR-27a could modulate proliferation and radiosensitivity of TNBC cells. CDC-27 is a direct target of miR-27a and its downregulation conferred increased radioresistance of the cells. CONCLUSIONS: The miR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. Testing miR-27a expression might be a useful way to identify a subgroup of patients who will benefit from an IR-based therapeutic approach.


Subject(s)
Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome/antagonists & inhibitors , MicroRNAs/physiology , Neoplasm Proteins/antagonists & inhibitors , Triple Negative Breast Neoplasms/radiotherapy , Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome/biosynthesis , Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome/genetics , Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome/physiology , Binding Sites , Breast/cytology , Cell Line, Tumor/radiation effects , Cells, Cultured , Conserved Sequence , Down-Regulation , Epithelial Cells/metabolism , Female , Gene Expression Regulation, Neoplastic/drug effects , HEK293 Cells , Humans , Molecular Targeted Therapy , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Neoplasm Proteins/physiology , Oligonucleotides/pharmacology , RNA Interference , RNA, Small Interfering/pharmacology , Radiation Tolerance/genetics , Recombinant Fusion Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/pathology , Tumor Stem Cell Assay
5.
Asian Pac J Cancer Prev ; 13(11): 5451-4, 2012.
Article in English | MEDLINE | ID: mdl-23317199

ABSTRACT

OBJECTIVE: The objective of this study was to evaluate the association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma (HCC). METHODS: A total of 689 HCC patients and 680 cancer-free subjects were enrolled. Human MDR1 gene polymorphisms were investigated by created restriction site- polymerase chain reaction (CRS-PCR) and DNA sequencing methods. Multiple logistic regression models were applied to estimate the association between MDR1 gene polymorphisms and susceptibility to HCC. RESULTS: We detected a novel c.4125A>C polymorphism and our findings suggested that this variant was significantly associated with susceptibility to HCC. A significantly increased susceptibility to HCC was noted in the homozygote comparison (CC versus AA: OR=1.621, 95% CI 1.143-2.300, χ2=7.4095, P=0.0065), recessive model (CC versus AC+AA: OR=1.625, 95% CI 1.167-2.264, χ2=8.3544, P=0.0039) and allele contrast (C versus A: OR=1.185, 95% CI 1.011-1.389, χ2=4.4046, P=0.0358). However, no significant increase was observed in the heterozygote comparison (AC versus AA: OR=0.995, 95% CI 0.794-1.248, χ2=0.0017, P=0.9672) and dominant model (CC+AC versus AA: OR=1.106, 95% CI 0.894-1.369, χ2=0.8560, P=0.3549). CONCLUSIONS: These findings suggest that the c.4125A>C polymorphism of the MDR1 gene might contribute to susceptibility to HCC in the Chinese population. Further work will be necessary to clarify the relationship between the c.4125A>C polymorphism and susceptibility to HCC on larger populations of diverse ethnicity.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Carcinoma, Hepatocellular/genetics , Genetic Predisposition to Disease , Liver Neoplasms/genetics , Polymorphism, Genetic/genetics , ATP Binding Cassette Transporter, Subfamily B , Carcinoma, Hepatocellular/epidemiology , Case-Control Studies , China/epidemiology , DNA/genetics , Female , Genotype , Humans , Liver Neoplasms/epidemiology , Male , Middle Aged , Polymerase Chain Reaction , Prognosis , Risk Factors
6.
Zhonghua Xin Xue Guan Bing Za Zhi ; 37(9): 809-12, 2009 Sep.
Article in Chinese | MEDLINE | ID: mdl-20128379

ABSTRACT

OBJECTIVE: To determine whether patients with suspected heart failure but preserved left ventricular ejection fraction (LVEF) have systolic dysfunction in left ventricular long axis detected by left ventricular systolic atrioventricular plane displacement (AVPD). METHODS: The data of 96 patients with heart failure who admitted to our hospital between August 2007 and October 2008 were collected. Heart failure with preserved LVEF was diagnosed in 48 patients and heart failure with reduced LVEF was diagnosed in another 48 patients. Fifty age-matched healthy subjects served as the control group. The NYHA classification, etiology of heart failure, AVPD and plasma NT-proBNP concentration were compared among the 3 groups. RESULTS: There was no difference in terms of NYHA classification between patients with preserved LVEF and reduced LVEF. Hypertension and coronary heart disease were often diagnosed in heart failure patients with preserved LVEF. The degree of AVPD decrease was more significant in heart failure patients with reduced LVEF than those with preserved LVEF. In all subjects, the AVPD was negatively correlated with the NT-proBNP concentration (r = -0.35, P < 0.05). CONCLUSION: Left ventricular systolic atrioventricular plane displacement was decreased in heart failure patients with preserved LVEF, therefore, besides "diastolic heart failure", systolic dysfunction was also impaired in these patients.


Subject(s)
Heart Failure/physiopathology , Ventricular Dysfunction, Left/physiopathology , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Echocardiography , Female , Heart Failure/diagnostic imaging , Heart Ventricles/physiopathology , Humans , Male , Middle Aged , Myocardial Contraction , Stroke Volume , Young Adult
7.
Zhonghua Zheng Xing Wai Ke Za Zhi ; 25(6): 433-6, 2009 Nov.
Article in Chinese | MEDLINE | ID: mdl-20209934

ABSTRACT

OBJECTIVE: To assess the feasibility of interstitial magnetic resonance lymphangiography (IMRL) with intracutaneous injection of gadobenate dimeglumine--a commercially available, non-ionic, extracellular paramagnetic contrast agent. METHODS: We studied 10 patients with lower extremity lymphedema. A mixture of 7.5 ml gadobenate dimeglumine and 0.5 ml 2% lidocaine were evenly subdivided into 8 portions and injected intracutaneously into each web space of both feet. For IMRL, a 3D fast spoiled gradient-recalled echo T1-weighted images with a fat saturation technique (T1 high resolution isotropic volume excitation, THRIVE) was performed. RESULTS: The beaded appearance of lymphatic vessels extending from the injection site were detected in 11 of 12 lower legs and the best delineation of lymphatic vessels was present at 15-30 minutes after injection. In 6 of 12 affected thighs, lymphatic vessels could be also visualized with the strongest enhancement at 45 minutes. CONCLUSION: IMRL is a safe and technically feasible new method which can effectively visualize the pathological lymphatic vessels in lower extremity lymphedema.


Subject(s)
Lower Extremity , Lymphedema/diagnostic imaging , Lymphography/methods , Adolescent , Adult , Aged , Child , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...